Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
ABL1 p.T315I,
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Cytarabine,
Methotrexate,
Ponatinib,
Prednisone,
Vincristine
|
|
Sensitivity (+) |
ABL1 p.T315I,
BCR::ABL1
|
Acute Lymphoid Leukemia |
Ponatinib
|
|
Sensitivity (+) |
ABL1 p.T315I
|
Chronic Myelogenous Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myeloid Leukemia, BCR-ABL1+ |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1,
CD22 +
|
Acute Lymphoid Leukemia |
Inotuzumab ozogamicin
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Imatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Imatinib
|
|
Sensitivity (+) |
ABL1 p.T315I
|
Chronic Myelogenous Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Ponatinib
|
|
Sensitivity (+) |
ABL1 p.T315I,
BCR::ABL1
|
Acute Lymphoid Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Dasatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Nilotinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Asciminib
|
|
Sensitivity (+) |
BCR::ABL1
|
Chronic Myelogenous Leukemia |
Bosutinib
|
|
Sensitivity (+) |
ABL1 p.T315I
|
Chronic Myelogenous Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Ponatinib
|
|
Sensitivity (+) |
ABL1 p.T315I,
BCR::ABL1
|
Acute Lymphoid Leukemia |
Ponatinib
|
|
Sensitivity (+) |
BCR::ABL1,
CD22 +
|
Acute Lymphoid Leukemia |
Inotuzumab ozogamicin
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1,
CD19 +
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|
Sensitivity (+) |
BCR::ABL1
|
Acute Lymphoid Leukemia |
Blinatumomab
|
|